Clinical trial
Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple…
NCT00396045 · University of Turin, Italy, Other · Completed
Key facts
| NCT number | NCT00396045 |
|---|---|
| Title | Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma |
| Official title | A Multicenter, Open Label Study of Oral Melphalan, Prednisone, and CC-5013 (Revlimid) (MPR) as Induction Therapy in Elderly Newly Diagnosed Multiple Myeloma Patients |
| Lead sponsor | University of Turin, Italy, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Revlimid (CC-5013) |
| Enrollment | 54 |
| Start date | Jan 1, 2005 |
| Completion | Jan 1, 2008 |
| First posted | Nov 6, 2006 |
| Last update posted | Nov 30, 2006 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: